symbol,statement_type,period_end,line_item,value
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Free Cash Flow,11852000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Repurchase Of Capital Stock,0.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Repayment Of Debt,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Issuance Of Capital Stock,73000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Capital Expenditure,-5116000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,End Cash Position,1200000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Beginning Cash Position,704000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Effect Of Exchange Rate Changes,-220000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Changes In Cash,716000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Financing Cash Flow,-2107000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Financing Charges,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Paid Cff,-176000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Cash Dividends Paid,-1078000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Common Stock Dividend Paid,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Common Stock Issuance,73000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Common Stock Payments,0.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Common Stock Issuance,73000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Issuance Payments Of Debt,-892000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Short Term Debt Issuance,-892000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Short Term Debt Payments,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Investing Cash Flow,-14145000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Investing Changes,-629000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Received Cfi,1466000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Dividends Received Cfi,33000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Investment Purchase And Sale,-11046000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of Investment,12927000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Investment,-23973000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Business Purchase And Sale,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Business,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Intangibles Purchase And Sale,-904000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of Intangibles,201000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Intangibles,-1105000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net PPE Purchase And Sale,-3061000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of PPE,950000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of PPE,-4011000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Operating Cash Flow,16968000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Taxes Refund Paid,-3726000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Working Capital,-1997000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Liabilities,-227000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Assets,-546000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Payable,403000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Inventory,-653000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Receivables,-593000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Other Non Cash Items,-1638000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Stock Based Compensation,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Provisionand Write Offof Assets,-22000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation And Amortization,2352000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Amortization Cash Flow,
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation,2352000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Investment Securities,-47000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,-8000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Sale Of PPE,-901000000.0
NATCOPHARM.NS,cashflow,2025-03-31 00:00:00,Net Income From Continuing Operations,22914000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Free Cash Flow,8529000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Repurchase Of Capital Stock,-2537000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Repayment Of Debt,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Issuance Of Capital Stock,0.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Capital Expenditure,-3587000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,End Cash Position,704000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Beginning Cash Position,1319000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Effect Of Exchange Rate Changes,65000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Changes In Cash,-680000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Financing Cash Flow,-2469000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Financing Charges,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Paid Cff,-181000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Cash Dividends Paid,-1708000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Common Stock Dividend Paid,-1708000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Common Stock Issuance,-2537000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Common Stock Payments,-2537000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Common Stock Issuance,0.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Issuance Payments Of Debt,1978000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Short Term Debt Issuance,1978000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Short Term Debt Payments,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Investing Cash Flow,-10327000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Investing Changes,-1325000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Received Cfi,585000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Dividends Received Cfi,3000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Investment Purchase And Sale,-6035000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of Investment,5824000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Investment,-11859000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Business Purchase And Sale,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Business,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Intangibles Purchase And Sale,-193000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of Intangibles,0.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Intangibles,-193000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net PPE Purchase And Sale,-3374000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of PPE,20000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of PPE,-3394000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Operating Cash Flow,12116000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Taxes Refund Paid,-2863000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Working Capital,-3094000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Liabilities,116000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Assets,-636000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Payable,-281000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Inventory,424000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Receivables,-3413000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Other Non Cash Items,-821000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Stock Based Compensation,
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Provisionand Write Offof Assets,227000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation And Amortization,1868000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Amortization Cash Flow,161000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation,1868000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Investment Securities,4000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,-8000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Sale Of PPE,17000000.0
NATCOPHARM.NS,cashflow,2024-03-31 00:00:00,Net Income From Continuing Operations,16735000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Free Cash Flow,6435000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Repurchase Of Capital Stock,-74000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Repayment Of Debt,
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Issuance Of Capital Stock,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Capital Expenditure,-2056000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,End Cash Position,1319000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Beginning Cash Position,1111000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Effect Of Exchange Rate Changes,118000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Changes In Cash,90000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Financing Cash Flow,-3630000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Financing Charges,
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Paid Cff,-142000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Cash Dividends Paid,-1004000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Common Stock Dividend Paid,-1004000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Common Stock Issuance,-74000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Common Stock Payments,-74000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Common Stock Issuance,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Issuance Payments Of Debt,-2390000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Short Term Debt Issuance,-2390000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Short Term Debt Payments,
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Investing Cash Flow,-4771000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Investing Changes,766000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Received Cfi,488000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Dividends Received Cfi,1000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Investment Purchase And Sale,-4275000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of Investment,1088000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Investment,-5363000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Business Purchase And Sale,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Business,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Intangibles Purchase And Sale,-593000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of Intangibles,
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Intangibles,-593000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net PPE Purchase And Sale,-1158000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of PPE,305000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of PPE,-1463000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Operating Cash Flow,8491000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Taxes Refund Paid,-1775000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Working Capital,627000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Liabilities,1027000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Assets,689000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Payable,1020000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Inventory,191000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Receivables,-2221000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Other Non Cash Items,-383000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Stock Based Compensation,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Provisionand Write Offof Assets,-239000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation And Amortization,1638000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Amortization Cash Flow,145000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation,1493000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Investment Securities,51000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,0.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Sale Of PPE,-178000000.0
NATCOPHARM.NS,cashflow,2023-03-31 00:00:00,Net Income From Continuing Operations,8619000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Free Cash Flow,-1962000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Repurchase Of Capital Stock,0.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Repayment Of Debt,
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Issuance Of Capital Stock,0.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Capital Expenditure,-2427000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,End Cash Position,1111000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Beginning Cash Position,258000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Effect Of Exchange Rate Changes,93000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Changes In Cash,760000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Financing Cash Flow,348000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Financing Charges,-18000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Paid Cff,-170000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Cash Dividends Paid,-822000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Common Stock Dividend Paid,-822000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Common Stock Issuance,0.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Common Stock Payments,0.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Common Stock Issuance,0.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Issuance Payments Of Debt,1382000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Short Term Debt Issuance,1382000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Short Term Debt Payments,
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Investing Cash Flow,-53000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Investing Changes,324000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Received Cfi,498000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Dividends Received Cfi,2000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Investment Purchase And Sale,2039000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of Investment,3246000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Investment,-1207000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Business Purchase And Sale,-1031000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Business,-1031000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Intangibles Purchase And Sale,-99000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of Intangibles,
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Intangibles,-99000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net PPE Purchase And Sale,-1790000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of PPE,538000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of PPE,-2328000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Operating Cash Flow,465000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Taxes Refund Paid,-482000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Working Capital,-2314000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Liabilities,-166000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Assets,-443000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Payable,74000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Inventory,564000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Receivables,-2352000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Other Non Cash Items,-229000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Stock Based Compensation,22000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Provisionand Write Offof Assets,271000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation And Amortization,1426000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Amortization Cash Flow,48000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation,1378000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Investment Securities,-14000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,-9000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Sale Of PPE,-427000000.0
NATCOPHARM.NS,cashflow,2022-03-31 00:00:00,Net Income From Continuing Operations,2022000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Free Cash Flow,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Repurchase Of Capital Stock,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Repayment Of Debt,-484000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Issuance Of Capital Stock,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Capital Expenditure,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,End Cash Position,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Beginning Cash Position,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Effect Of Exchange Rate Changes,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Changes In Cash,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Financing Cash Flow,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Financing Charges,-95000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Paid Cff,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Cash Dividends Paid,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Common Stock Dividend Paid,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Common Stock Issuance,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Common Stock Payments,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Common Stock Issuance,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Issuance Payments Of Debt,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Short Term Debt Issuance,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Short Term Debt Payments,-484000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Investing Cash Flow,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Investing Changes,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Received Cfi,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Dividends Received Cfi,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Investment Purchase And Sale,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of Investment,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Investment,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Business Purchase And Sale,0.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Business,0.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Intangibles Purchase And Sale,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of Intangibles,23000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Intangibles,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net PPE Purchase And Sale,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of PPE,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of PPE,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Operating Cash Flow,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Taxes Refund Paid,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Working Capital,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Liabilities,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Assets,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Payable,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Inventory,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Receivables,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Other Non Cash Items,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Stock Based Compensation,126000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Provisionand Write Offof Assets,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation And Amortization,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Amortization Cash Flow,24000000.0
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Investment Securities,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Sale Of PPE,
NATCOPHARM.NS,cashflow,2021-03-31 00:00:00,Net Income From Continuing Operations,
